	US 12,252,486 B2
	Solid state forms
Mary Chaves, Arlington, MA (US); Ron C. Kelly, Westlake Village, CA (US); Prashant Agarwal, Chelsea, MA (US); Stephan D. Parent, West Lafayette, IN (US); Darren Leonard Reid, Belmont, MA (US); and Roman Shimanovich, Brighton, MA (US)
Assigned to Amgen Inc., Thousand Oaks, CA (US)
Appl. No. 17/612,717
Filed by Amgen Inc., Thousand Oaks, CA (US)
PCT Filed May 20, 2020, PCT No. PCT/US2020/033832 § 371(c)(1), (2) Date Nov. 19, 2021, PCT Pub. No. WO2020/236948, PCT Pub. Date Nov. 26, 2020.
Claims priority of provisional application 62/851,049, filed on May 21, 2019.
Prior Publication US 2022/0235045 A1, Jul. 28, 2022
Int. Cl. C07D 471/04 (2006.01); A61P 35/00 (2006.01)

CPC C07D 471/04 (2013.01) [A61P 35/00 (2018.01); C07B 2200/13 (2013.01)]

54 Claims

1. A compound, wherein the compound is a crystalline hydrochloride salt of the M atropisomer of 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(2-propanyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(2-propenoyl)-1-piperazinyl)pyrido[2,3-d]pyrimidin-2 (1H)-one.